Nil Saez Calveras

TRIDENT trial: For patients with intracerebral hemorrhage, blood-pressure reduction is the only strategy to prevent recurrence, but long-term blood-pressure control is often inadequate. Research findings on a single pill containing three antihypertensive agents are summarized in a new Quick Take video. nejm.org/doi/full/10.10…

And that’s a wrap! What an amazing #AANAM in Chicago, surrounded by great company. Already counting down to D.C. in 2027! @AANmember @UTSW_NeuroRes

Lecanemab and long term Alzheimer’s: are we finally bending the curve? Low baseline tau seems to be important. Amyloid refers to sticky protein clumps in the brain that are believed to contribute to Alzheimer's disease. Christopher van Dyck and colleagues describe in an abstract from this years American Academy of Neurology meeting the most recent findings from the Clarity AD open label extension study examining up to 48 months of treatment w/ lecanemab in early Alzheimer’s disease. Key points: - Lecanemab treatment showed continued slowing of cognitive and functional decline through 48 months compared to matched controls. - Treatment differences increased over time suggesting a possible cumulative or durable disease modifying effect. - A meaningful proportion of participants showed no decline or even improvement especially in those w/ low baseline tau. My take: This is important as longitudinal signals in Alzheimer’s disease matter. The idea that treatment effects may grow over time is provocative and raises the possibility that early and sustained intervention could meaningfully alter trajectory. At the same time we must remain cautious as these are open label extension data, and longer term real world validation will also matter. Here are 5 points that resonated w/ me: 1- Early treatment may be key to maximizing benefit in Alzheimer’s disease. 2- Slowing decline over years rather than months is what folks and families care about most. 3- The subgroup w/ low tau may represent a window where intervention is most effective. 4- Safety signals appear stable over time which is reassuring for ongoing use. 5- The future may include combining amyloid therapies w/ other approaches to further shift the disease course. index.mirasmart.com/AAN2026/PDFfil… @ParkinsonDotOrg #parkinson #alzheimer @alzassociation

New @AJR_Radiology Accepted Manuscript: "MRI-Guided HIFU in Movement Disorders: Targeting Pathologic Brain Circuits With Precision Imaging, From the AJR Special Series on Critical Anatomy" By Dr Asturias & team @UTSW_Radiology ajronline.org/doi/10.2214/AJ…

High-Level Alzheimer Disease Neuropathological Change Following Iatrogenic Exposure jamanetwork.com/journals/jaman…

✨ Come meet #TeamNeuro at the 2026 #AANAM. We had such a blast last year Stop by, say hi, and learn more at 🖥️ Poster sessions: bit.ly/4tcMM3U 🤝 Trainee and Faculty Networking Reception @AANmember

Congratulations to our own Dr. Mayank Verma for the highly competitive Dean’s Scholar award!! Dr. Verma is an excellent physician scientist and also a highly valued member of the Child Neurology resident Scholarly Oversight Committee

1/ We are thrilled to announce that our American branch of the Laboratory of Human Genetics of Infectious Diseases (HGID) will relocate to @UTSWMedCenter in Dallas, Texas, effective July 1, 2026 J

Welcome to our newest neurons - we can't wait to learn with you! #nmatch2026 @UTSWPedsNeuro @UTSW_Psychiatry @NMatch2026 @AANmember @UTSWBrain

Deadline is Friday, May 1st! 📣 Submit your application and you could win funding for research in an area of your interest. Grant winner(s) will be announced at the summer TNS conference in San Antonio this July. More info and application: bit.ly/3vSFIl9

Introducing our newly selected chief residents for the upcoming 2026-2027 academic year. 🚀 Preeti Mohan, M.D. - Clinic Chief 🚀 Tabarak Mian, M.D. - Academic Chief 🚀 Jesse Maguire, M.D. - Scheduling Chief 🚀 Kesar Dhillon, M.D. - Scheduling Chief @UTSWNeurology

Thurs. can’t get here fast enough! There is something special about getting the #NM community under one roof. Whether you’re coming for the keynote sessions or the hallway conversations that spark the next big idea, #CarrellKrusen is all about connection. @ShaidaKhanDO @kbatleymd

Congratulations to Tope Adedolapo, M.D. M.S., M.B.A., Enrique Chiu Han M.D., Nabila Haque, and Renae White, M.D., on their election to the UTSW Chapter of the @AOA_society as resident nominees! This is a great honor and well-deserved! #UTSW #Brain #Psychiatry

Excited to share this preprint in collaboration with co-author Bert M Verheijen and the Ying Lu lab! Using tau alanine scanning we identified that tau seeds in the brain and spinal cord of ALS/PDC cases exhibit a CTE-like profile @MDiamond_Lab @UTSWBrain

Oveporexton produced significant improvements in sustained attention, memory, and executive function among adults with #NarcolepsyType1. ja.ma/3MoXjc7

Stay ahead of rapidly evolving stroke management. The Cerebrovascular Diseases & Stroke Symposium 2025 offers expert updates on acute intervention, secondary prevention, and complex cases. Dec 13 in Dallas. Register here: bit.ly/44BNUnQ

Discussions on EEG education in neurology residency program happening now at #AES2025 Dr Doyle Yuan @fabnascimen @RoohiKatyal @UTSW_NeuroRes @UTSWNeurology @adam_greenblatt @namesare4babies @BrandonWestove5

🎉 Proud to honor Dr. Jaya Trivedi & Dr. Padraig O'Suilleabhain as the 2025 recipients of the Loehr Lifetime Achievement Award at UT Southwestern — recognizing decades of outstanding patient care, research, and leadership. #HealthcareExcellence bit.ly/4o6wFBY

"An early and reliable 4R-tau biomarker might help guide the timing of disease-modifying therapies." Read more about copathology in atypical Parkinsonism in this Viewpoint. ja.ma/48CPrwf

Immensely grateful to @txalzresearch for their support of this project, and to @MDiamond_Lab and everyone at @UtsWcand for the mentorship that made it possible! @UTSWBrain